AOD-9604
Also known as Anti-Obesity Drug 9604
Investigational fragment of human growth hormone studied for fat metabolism without classical GH side effects.
This compound was removed from FDA Category 2 in 2026, but final action on the 503A compounding list is still pending. Allora does not currently dispense it — join the waitlist and we will notify you if it becomes available through our licensed pharmacy partners.
Mechanism of action
How AOD-9604 works
Acts on adipose tissue to favor lipolysis without binding to growth hormone receptors that drive somatic growth signals.
Areas of study
What AOD-9604 is studied for
- check
Adjunctive support in body composition protocols
- check
Lipolysis modulation under physician supervision
Considerations
Important things your physician will discuss
This is general clinical context — not medical advice. Your evaluation determines whether AOD-9604 is appropriate for you.
- info
Removed from FDA Category 2 in 2026; final action on the 503A compounding list is pending — currently offered as educational information and waitlist only
- info
Investigational status — clinical evidence is still emerging
- info
Not a replacement for nutrition, training, or core metabolic therapies
Related peptides
More from the Metabolic category
Semaglutide / Tirzepatide
Incretin-class therapies that modulate appetite, slow gastric emptying, and improve insulin response.
View peptide arrow_outwardGHRH analogTesamorelin
Growth-hormone-releasing-hormone analog studied for visceral adipose tissue reduction and body composition shifts.
View peptide arrow_outwardLipotropic cofactor blendLipotropic B-12 / MIC
Compounded blend of lipotropic cofactors (methionine, inositol, choline) with methylcobalamin B-12, used to support energy and lipid metabolism.
View peptide arrow_outwardThis compound is pending FDA compounding review.
We don't dispense it today. Join the waitlist and we'll notify you if it becomes available through our licensed pharmacy partners.